Literature DB >> 33716160

Serous business: Delineating the broad spectrum of diseases with subretinal fluid in the macula.

Elon H C van Dijk1, Camiel J F Boon2.   

Abstract

A wide range of ocular diseases can present with serous subretinal fluid in the macula and therefore clinically mimic central serous chorioretinopathy (CSC). In this manuscript, we categorise the diseases and conditions that are part of the differential diagnosis into 12 main pathogenic subgroups: neovascular diseases, vitelliform lesions, inflammatory diseases, ocular tumours, haematological malignancies, paraneoplastic syndromes, genetic diseases, ocular developmental anomalies, medication-related conditions and toxicity-related diseases, rhegmatogenous retinal detachment and tractional retinal detachment, retinal vascular diseases, and miscellaneous diseases. In addition, we describe 2 new clinical pictures associated with macular subretinal fluid accumulation, namely serous maculopathy with absence of retinal pigment epithelium (SMARPE) and serous maculopathy due to aspecific choroidopathy (SMACH). Differentiating between these various diseases and CSC can be challenging, and obtaining the correct diagnosis can have immediate therapeutic and prognostic consequences. Here, we describe the key differential diagnostic features of each disease within this clinical spectrum, including representative case examples. Moreover, we discuss the pathogenesis of each disease in order to facilitate the differentiation from typical CSC.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Central serous chorioretinopathy (CSC); Differential diagnosis; Retinal disease; Serous fluid accumulation; Serous maculopathy

Mesh:

Year:  2021        PMID: 33716160     DOI: 10.1016/j.preteyeres.2021.100955

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  5 in total

1.  Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3.

Authors:  Helena M A Feenstra; Elon H C van Dijk; Thomas J van Rijssen; Roula Tsonaka; Roselie M H Diederen; Carel B Hoyng; Reinier O Schlingemann; Camiel J F Boon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-10-07       Impact factor: 3.535

2.  The Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathy.

Authors:  Joost Brinks; Elon H C van Dijk; Szymon M Kiełbasa; Hailiang Mei; Isa van der Veen; Hendrika A B Peters; Hetty C M Sips; Robbert G E Notenboom; Paul H A Quax; Camiel J F Boon; Onno C Meijer
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 5.958

3.  A Splicing Mutation in Slc4a5 Results in Retinal Detachment and Retinal Pigment Epithelium Dysfunction.

Authors:  Gayle B Collin; Lanying Shi; Minzhong Yu; Nurten Akturk; Jeremy R Charette; Lillian F Hyde; Sonia M Weatherly; Martin F Pera; Jürgen K Naggert; Neal S Peachey; Patsy M Nishina; Mark P Krebs
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 5.923

4.  Bilateral diffuse uveal melanocytic proliferation: Report of a novel optical coherence tomography finding and clinical response to plasmapheresis.

Authors:  Fares Antaki; Bruna Gil Ferreira; Jean-Yves Sahyoun; Karim Hammamji
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-30

5.  From Genes, Proteins, and Clinical Manifestation: Why Do We Need to Better Understand Age-Related Macular Degeneration?

Authors:  Steffen Schmitz-Valckenberg; Moussa A Zouache; Gregory S Hageman; Monika Fleckenstein
Journal:  Ophthalmol Sci       Date:  2022-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.